Looking at the filing, I can confirm this is Ovid Therapeutics Inc.'s Form 10-Q for the quarterly period ended June 30, 2026, filed August 13, 2026. The ticker is OVID on The Nasdaq Stock Market LLC (NASDAQ:OVID). The filing content provided is truncated before the financial statements are populated with figures, so I will report only what is confirmable from the text.

Ovid Therapeutics Inc. filed a Form 10-Q with the U.S. Securities and Exchange Commission on August 13, 2026, covering the quarterly period ended June 30, 2026, disclosing the company's financial condition and operations as a non-accelerated, smaller reporting company listed on NASDAQ:OVID.

Key Highlights

  • Share count: As of August 11, 2026, Ovid Therapeutics Inc. had 195,297,857 shares of common stock, $0.001 par value per share, outstanding.
  • Exchange listing: Common stock is registered on The Nasdaq Stock Market LLC under the trading symbol OVID.
  • Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company, and is not an emerging growth company.
  • Principal offices: The registrant is headquartered at 441 Ninth Avenue, 14th Floor, New York, New York 10001.
  • Reporting period: The quarterly report covers the period ended June 30, 2026.
  • Shell company status: The registrant indicated it is not a shell company as defined under Rule 12b-2 of the Exchange Act.

Ovid Therapeutics Reports Quarterly Filing Status and Share Count for June 30, 2026

Ovid Therapeutics Inc., a Delaware-incorporated biopharmaceutical company, submitted its quarterly report for the period ended June 30, 2026. According to the filing, the company describes itself as focused on identifying, acquiring, and in-licensing novel drug candidates with significant commercial potential. The registrant's common stock, with a par value of $0.001 per share, is listed on The Nasdaq Stock Market LLC under the symbol OVID, as stated on the cover page of the filing.

The filing confirms that as of August 11, 2026, Ovid Therapeutics had 195,297,857 shares of common stock outstanding. The company checked the box indicating it has filed all reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and that it has submitted all required Interactive Data Files electronically pursuant to Rule 405 of Regulation S-T, according to the cover page disclosures.

The quarterly report includes unaudited condensed consolidated financial statements, management's discussion and analysis, risk factors, and other required disclosures. The filing notes that statements about future events, including expectations regarding clinical trial timing, cash runway, and pipeline development, are forward-looking statements subject to risks and uncertainties described in Part II, Item 1A of the report. The company stated it "assume[s] no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future."

What Was Disclosed

Ovid Therapeutics Inc. filed its Form 10-Q for the quarter ended June 30, 2026, disclosing 195,297,857 shares outstanding as of August 11, 2026, its classification as a non-accelerated smaller reporting company, and its continued listing on NASDAQ:OVID.